La; Casce, A. S. (2018). Brentuximab vedotin plus bendamustine: A highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. American Society of Hematology (ASH).
Chicago Style (17th ed.) CitationLa; Casce, A. S. Brentuximab Vedotin Plus Bendamustine: A Highly Active First Salvage Regimen for Relapsed or Refractory Hodgkin Lymphoma. American Society of Hematology (ASH), 2018.
MLA (9th ed.) CitationLa; Casce, A. S. Brentuximab Vedotin Plus Bendamustine: A Highly Active First Salvage Regimen for Relapsed or Refractory Hodgkin Lymphoma. American Society of Hematology (ASH), 2018.
Warning: These citations may not always be 100% accurate.